AU2003223014A1 - Pna monomer and precursor - Google Patents

Pna monomer and precursor

Info

Publication number
AU2003223014A1
AU2003223014A1 AU2003223014A AU2003223014A AU2003223014A1 AU 2003223014 A1 AU2003223014 A1 AU 2003223014A1 AU 2003223014 A AU2003223014 A AU 2003223014A AU 2003223014 A AU2003223014 A AU 2003223014A AU 2003223014 A1 AU2003223014 A1 AU 2003223014A1
Authority
AU
Australia
Prior art keywords
halogenated
oligomers
protected
natural
nucleobase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003223014A
Other languages
English (en)
Inventor
Sang Youl Ahn
Hoon Choi
Jae Hoon Jeon
Sung Kee Kim
Hyunil Lee
Sung Hee Lee
Jong Chan Lim
Won Jun Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panagene Inc
Original Assignee
Panagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panagene Inc filed Critical Panagene Inc
Publication of AU2003223014A1 publication Critical patent/AU2003223014A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70Sulfur atoms
    • C07D277/76Sulfur atoms attached to a second hetero atom
    • C07D277/80Sulfur atoms attached to a second hetero atom to a nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11Compounds covalently bound to a solid support
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
AU2003223014A 2002-04-26 2003-04-28 Pna monomer and precursor Abandoned AU2003223014A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020020023157A KR20030084444A (ko) 2002-04-26 2002-04-26 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
KR2002/23157 2002-04-26
PCT/IB2003/001595 WO2003091231A1 (en) 2002-04-26 2003-04-28 Pna monomer and precursor

Publications (1)

Publication Number Publication Date
AU2003223014A1 true AU2003223014A1 (en) 2003-11-10

Family

ID=29267903

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003223014A Abandoned AU2003223014A1 (en) 2002-04-26 2003-04-28 Pna monomer and precursor

Country Status (10)

Country Link
US (7) US6969766B2 (US07125994-20061024-C00039.png)
EP (2) EP2174936B1 (US07125994-20061024-C00039.png)
JP (2) JP4417728B2 (US07125994-20061024-C00039.png)
KR (2) KR20030084444A (US07125994-20061024-C00039.png)
CN (1) CN100347161C (US07125994-20061024-C00039.png)
AT (1) ATE453631T1 (US07125994-20061024-C00039.png)
AU (1) AU2003223014A1 (US07125994-20061024-C00039.png)
DE (1) DE60330766D1 (US07125994-20061024-C00039.png)
DK (2) DK1501812T3 (US07125994-20061024-C00039.png)
WO (1) WO2003091231A1 (US07125994-20061024-C00039.png)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100464261B1 (ko) * 2002-01-24 2005-01-03 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US7211668B2 (en) * 2003-07-28 2007-05-01 Panagene, Inc. PNA monomer and precursor
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
CA2610710C (en) 2005-06-02 2016-10-11 Advandx, Inc. Peptide nucleic acid probes for analysis of microorganisms
WO2009032901A1 (en) * 2007-09-04 2009-03-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biosensors and related methods
US9200276B2 (en) 2009-06-01 2015-12-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
KR101944119B1 (ko) 2009-11-13 2019-01-30 사렙타 쎄러퓨틱스 인코퍼레이티드 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법
US20120309684A1 (en) 2009-11-30 2012-12-06 Isis Innovation Limited Conjugates for delivery of biologically active compounds
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
WO2011113015A2 (en) 2010-03-12 2011-09-15 Avi Biopharma, Inc. Antisense modulation of nuclear hormone receptors
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
WO2011139799A2 (en) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
EP2563912B1 (en) 2010-04-29 2018-09-05 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
CN102985103A (zh) 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
US9238042B2 (en) 2010-05-13 2016-01-19 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
WO2011143482A2 (en) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
JP6027965B2 (ja) 2010-05-17 2016-11-16 エータイアー ファーマ, インコーポレイテッド ロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
EP2608801B1 (en) 2010-08-25 2019-08-21 aTyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
US10100305B2 (en) 2011-07-15 2018-10-16 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
DK2788487T3 (en) 2011-12-08 2018-07-23 Sarepta Therapeutics Inc Oligonucleotide Analogs Targeted against HUMAN LMNA
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
KR20210088009A (ko) 2013-09-05 2021-07-13 사렙타 쎄러퓨틱스, 인코퍼레이티드 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
EP3221445B1 (en) 2014-11-20 2021-07-14 The Regents of The University of California Compositions and methods related to hematologic recovery
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
MA50829A (fr) 2015-06-01 2018-04-11 Sarepta Therapeutics Inc Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
KR102522059B1 (ko) 2016-04-18 2023-04-14 사렙타 쎄러퓨틱스 인코퍼레이티드 안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
EA201892467A1 (ru) 2016-04-29 2019-05-31 Сарепта Терапьютикс, Инк. Олигонуклеотидные аналоги, нацеленные на lmna человека
EP3478697A1 (en) 2016-06-30 2019-05-08 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
WO2018017814A1 (en) 2016-07-20 2018-01-25 President And Fellows Of Harvard College Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
WO2018053142A2 (en) 2016-09-14 2018-03-22 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
WO2018118662A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
KR102552428B1 (ko) 2016-12-19 2023-07-06 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
CN110337308B (zh) 2016-12-19 2023-09-01 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
WO2019067981A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
JP2020536057A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーを処置するための併用療法
EP3687547A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP4219717A3 (en) 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
WO2020004980A1 (ko) * 2018-06-27 2020-01-02 주식회사 시선바이오머티리얼스 Pna 올리고머의 제조방법
TW202020153A (zh) 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
US11273137B2 (en) 2018-09-04 2022-03-15 Board Of Trustees Of Michigan State University Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
WO2020123574A1 (en) 2018-12-13 2020-06-18 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
CN114040799A (zh) 2019-03-12 2022-02-11 哈佛大学校长及研究员协会 治疗癌症的方法和组合物
US20220193246A1 (en) 2019-04-18 2022-06-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US20220226269A1 (en) 2019-06-12 2022-07-21 President And Fellows Of Harvard College Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
WO2021133032A1 (ko) * 2019-12-24 2021-07-01 주식회사 시선바이오머티리얼스 개질된 감마탄소 골격 화합물 및 이의 제조방법
KR102403904B1 (ko) * 2019-12-24 2022-06-02 주식회사 시선바이오머티리얼스 용액공정상 pna 올리고머의 제조방법
AU2021232598A1 (en) 2020-03-04 2022-09-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for sensitization of tumor cells to immune therapy
US20230285357A1 (en) 2020-05-27 2023-09-14 The Regents Of The University Of California Compositions and methods for transdifferentiating cells
WO2022056454A2 (en) 2020-09-14 2022-03-17 President And Fellows Of Harvard College Methods and compositions for treating hpv-positive cancers
EP4213947A2 (en) 2020-09-16 2023-07-26 President and Fellows of Harvard College Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
CA3233242A1 (en) 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
WO2023091704A1 (en) 2021-11-18 2023-05-25 Circularis Biotechnologies, Inc. Compositions and methods for production of circular nucleic acid molecules
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2135543A1 (de) * 1971-07-16 1973-01-25 Boehringer Mannheim Gmbh Benzthiazolderivate enthaltende arzneimittel
IT1059127B (it) * 1976-04-15 1982-05-31 Montedison Spa Eteri e tioeteri benzilici o feni lici a catena alifatica lineare con terminale alogenato ad attivi ta ormonica giovanile e acaric/da
US4204870A (en) 1978-07-25 1980-05-27 Eastman Kodak Company Photographic products and processes employing novel nondiffusible heterocyclyazonaphthol dye-releasing compounds
JPS5827273B2 (ja) * 1980-06-12 1983-06-08 三新化学工業株式会社 ベンゾチアゾ−ル−2−スルホンアミド化合物の製造方法
US6228982B1 (en) * 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US6713602B1 (en) * 1991-05-24 2004-03-30 Ole Buchardt Synthetic procedures for peptide nucleic acids
JPH05140115A (ja) * 1991-11-14 1993-06-08 Sanshin Chem Ind Co Ltd スルホンアミド系化合物及びゴム組成物
US6277603B1 (en) * 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
JPH06298749A (ja) * 1993-02-19 1994-10-25 Asahi Chem Ind Co Ltd ベンゾチアゾールスルホンアミド誘導体
US6350853B1 (en) * 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
RU2118322C1 (ru) * 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
US5435939A (en) * 1993-07-07 1995-07-25 Isp Investments Inc. Stable emulsifiable gel matrix and aqueous macroemulsion prepared therefrom
US6133444A (en) 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
JP2001518054A (ja) 1995-06-07 2001-10-09 パーセプティブ バイオシステムズ,インコーポレーテッド Pna−dnaキメラと、このキメラ合成用のpnaシントン
DE19532553A1 (de) * 1995-09-04 1997-03-06 Hoechst Ag Verfahren zur Herstellung substituierter N-Ethyl-Glycinderivate
JPH11199573A (ja) * 1998-01-07 1999-07-27 Yamanouchi Pharmaceut Co Ltd 5ht3受容体作動薬及び新規ベンゾチアゾール誘導体
HUP0101810A3 (en) * 1998-01-27 2002-05-28 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them
AU4965499A (en) 1998-07-09 2000-02-01 Biocept, Inc. Method of using an improved peptide nucleic acid universal library to optimize dna sequence hybridation
SE9802538D0 (sv) 1998-07-13 1998-07-13 Astra Ab New pharmaceutically active compounds
KR100464261B1 (ko) * 2002-01-24 2005-01-03 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US7211668B2 (en) * 2003-07-28 2007-05-01 Panagene, Inc. PNA monomer and precursor

Also Published As

Publication number Publication date
US7145006B2 (en) 2006-12-05
US6969766B2 (en) 2005-11-29
EP2174936A1 (en) 2010-04-14
EP1501812B1 (en) 2009-12-30
WO2003091231A1 (en) 2003-11-06
KR20040062611A (ko) 2004-07-07
JP4927105B2 (ja) 2012-05-09
EP1501812A4 (en) 2006-05-24
JP2005536459A (ja) 2005-12-02
DE60330766D1 (de) 2010-02-11
US20030225252A1 (en) 2003-12-04
US7125994B2 (en) 2006-10-24
KR20030084444A (ko) 2003-11-01
US7371860B2 (en) 2008-05-13
US20060030709A1 (en) 2006-02-09
EP1501812A1 (en) 2005-02-02
KR100555204B1 (ko) 2006-03-03
US7179896B2 (en) 2007-02-20
DK2174936T3 (da) 2013-11-04
DK1501812T3 (da) 2010-03-22
JP4417728B2 (ja) 2010-02-17
JP2009143937A (ja) 2009-07-02
US20060003374A1 (en) 2006-01-05
US7371859B2 (en) 2008-05-13
EP2174936B1 (en) 2013-09-04
CN1659153A (zh) 2005-08-24
US20050250786A1 (en) 2005-11-10
US20050250785A1 (en) 2005-11-10
CN100347161C (zh) 2007-11-07
US7411065B2 (en) 2008-08-12
US20060008835A1 (en) 2006-01-12
US20050283005A1 (en) 2005-12-22
ATE453631T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
AU2003223014A1 (en) Pna monomer and precursor
ATE447569T1 (de) Pna-monomer und vorstufe
DE60328866D1 (de) Peptid-nukleinsäure-oligomere aus 1-benzol sulfonyl-3-amino säure seitenkette-4-(2-nukleo base(acetyl))piperazin-2-onen
WO2003064455A3 (en) Macrocyclic peptides active against the hepatitis c virus
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
TWI266761B (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
HK1048465A1 (en) Aminobenzophenones as inhibitors of il-1B and tnf-a.
DK0785208T3 (da) Phosphonat-nukleotid-forbindelser
NZ260159A (en) N-bicyclic nitrogen compounds and medicaments
HUP0302193A2 (hu) 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
IN2012DN02546A (US07125994-20061024-C00039.png)
HK1048303A1 (en) Aminobenzophenoses as inhibitors of il-1b and tnf -a.
WO2003020703A1 (fr) Compose d'amine cyclique
DK1202954T3 (da) Nye aminobenzophenoner
WO2004075858A3 (en) Flavone acetic acid analogs and methods of use thereof
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same
WO2005016916A3 (fr) Quinolines substituées comme antimicrobiens
WO2001060822A8 (fr) Derives d'aminoacides et leur utilisation en tant qu'inhibiteurs de la nep, l'ace et l'ece
EP1069115A4 (en) METHOD FOR PRODUCING OXAZOLIDIN-2-ONE COMPOUNDS
WO2003033447A1 (fr) Composes lumineux et reactifs de marquage l'utilisant
BG103554A (en) Substituted pyrazol-3-ylbenzazoles
EP1057485A4 (en) POTASSIUM CHANNEL ACTIVATORS
WO2003043582A3 (en) Modulators of rho c activity
DE60214414D1 (de) Peptidderivat, pharmazeutisch unbedenkliches salz davon, verfahren zu dessen herstellung und dessen verwendung
EP1484319A4 (en) CHAIN OLIGOMIC ACID ETHANOL

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase